A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment — Stella

Home/Hepatic Impairment (HI)/

View on ClinicalTrials.gov

Recruiting

Back to Hepatic Impairment (HI) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

The University of Miami Division of Clinical Pharmacology, Miami, Florida

Orlando Clinical Research Center, Orlando, Florida

Key details

Phase

Early testing

Sponsor

Edgewise Therapeutics, Inc.

Enrollment target

~32 participants

Started

January 2026

Primary completion

May 2026

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.